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Abstract
The release of new DNA-based diagnostic tools has increased tremendously in companion animals. Over 70
different DNA variants are now known for the cat, including DNA variants in disease-associated genes and genes
causing aesthetically interesting traits. The impact genetic tests have on animal breeding and health management is
significant because of the ability to control the breeding of domestic cats, especially breed cats. If used properly, genetic
testing can prevent the production of diseased animals, causing the reduction of the frequency of the causal variant in
the population, and, potentially, the eventual eradication of the disease. However, testing of some identified DNA variants
may be unwarranted and cause undo strife within the cat breeding community and unnecessary reduction of gene
pools and availability of breeding animals. Testing for mucopolysaccharidosis Type VI (MPS VI) in cats, specifically the
genetic testing of the L476P (c.1427T>C) and the D520N (c.1558G>A) variants in arylsulfatase B (ARSB), has come under
scrutiny. No health problems are associated with the D520N (c.1558G>A) variant, however, breeders that obtain positive
results for this variant are speculating as to possible correlation with health concerns. Birman cats already have a markedly
reduced gene pool and have a high frequency of the MPS VI D520N variant. Further reduction of the gene pool by
eliminating cats that are heterozygous or homozygous for only the MPS VI D520N variant could lead to more inbreeding
depression effects on the breed population. Herein is debated the genetic testing of the MPS VI D520N variant in cats.
Surveys from different laboratories suggest the L476P (c.1427T>C) disease-associated variant should be monitored in the
cat breed populations, particularly breeds with Siamese derivations and outcrosses. However, the D520N has no evidence
of association with disease in cats and testing is not recommended in the absence of L476P genotyping. Selection
against the D520N is not warranted in cat populations. More rigorous guidelines may be required to support the genetic
testing of DNA variants in all animal species.
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Background
Genetic testing represents one of the most important
hot topics in the field of veterinary small animal practice
[1, 2]. The discovery and release of DNA-based diagnos-
tics has tremendously increased, and the impact of these
tests on animal breeding and health and population
management is significant. All DNA tests need extensive
“vetting” by the research community to document sensi-
tivity, specificity and correlation with disease since the
downstream consequences of publishing ambiguous or
benign genetic variants have the potential to dramatic-
ally impact the genetic health of a population.
One recent example of a controversial DNA test in
cats was the A31P and A74T variants in myosin-binding
protein C3 (MYBPC3) for hypertrophic cardiomyopathy
(HCM) [3]. The A31P variant has a strong correlation
with disease – as an indicator of risk, with a late-onset
Mendelian autosomal dominant transmission, in Maine
Coon cats. However, an A74T variant was presented in
an abstract and suggested as causative for the same dis-
ease, which elicited a strong debate in the veterinary
community [4]. Genetic testing was initiated by several
commercial laboratories in worldwide cat breed popula-
tions. However, data strongly indicated that the A74T
was a common polymorphism in a large number of
breeds, and not significantly correlated to HCM [5].
Therefore, the A74T DNA variant testing was subse-
quently removed from many commercial laboratory
offerings and no breeding decisions should be influ-
enced by the presence or absence of this variant in a
domestic cat.
A similar situation has recently developed for the gen-
etic testing of mucopolysaccharidosis Type VI (MPS VI),
an arylsulfatase B (ARSB) variant in cat breeds [6–9].
The published phenotypes and implications of the
L476P (c.1427 T > C) variant in ARSB that causes a
* Correspondence: lyonsla@missouri.edu
1Department of Veterinary Medicine and Surgery, College of Veterinary
Medicine, University of Missouri – Columbia, Columbia, MO 65211, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lyons et al. BMC Veterinary Research  (2016) 12:136 
DOI 10.1186/s12917-016-0764-y
severe form of MPS VI have been recognized for many
years [10]. However, a second variant of ARSB was identi-
fied within the same experimental feline colony [11, 12].
Several laboratories now offer this MPS VI D520N “mild”
DNA test to the cat breeding community. Unlike HCM,
veterinarians and cat owners are less familiar with MPS VI,
both in regards to clinical presentation and disease course.
Unarmed with the proper knowledge and poor availabil-
ity of genetic counselling, breeders have become alarmed
since many cats have been genotyped as carriers or homo-
zygous for the D520N ARSB variant. A wave of genotyp-
ing in Birmans for the D520N variant has escalated the
concern with breeders, who are now attributing pyometra,
pregnancy loss, infertility and other health problems as a
result of the variant (Personal communication – several
authors). Hence, the impetus for this positional paper and
a perfect example of the questions the scientific, veterinar-
ian and breeder community will frequently address in the
future. The questions are: does this mutation cause a “real
disease”, a “dysfunction” and is it worthy of negative selec-
tion and elimination from breeding programs? Does this
variant predict a strong association with disease – as a risk
indicator? A quick and massive selection for any genetic
traits can lead to a drastic reduction of the genetic vari-
ability in the breed and the potential emergence of other
problems, potentially more devastating, such as the severe
form of MPS VI.
The authors consider the ARSB D520N variant not
causative of a dysfunction or health concern unless
present in combination with the ARSB L476P variant.
Selection against cats with the D520N variant is only
warranted if also testing for L476P. However, the
L476P variant has not been demonstrated to be present
in cat breed and domestic cat populations that have
been tested to date. Presented is an evaluation of
current genotyping data that supports this position.
What is mucopolysaccharidosis Type VI (MPS VI)?
The lysosomal storage diseases (LSD) form a diverse
group of conditions linked by the common pathological
feature of abnormal accumulation of metabolites within
cells (for review) [13]. LSD results from a deficiency of
an enzyme of one of the lysosomal catabolic pathways.
The lysosomes provide a suitable environment for
enzyme-catalyzed hydrolysis, keeping other cellular
structures protected from the harmful effects of uncon-
fined degradative enzymes. The LSD group is organized
into subgroup classifications comprised of more than
30 different diseases based of the metabolic pathways
affected and the type of storage identified. Humans
with MPS have at least seven different disease entities
that include skeletal, cardiovascular, neurological and
ocular abnormalities and these same conditions are
found in MPS cats [6–8, 14–18].
MPS VI in humans
In humans, MPS VI, or Maroteaux - Lamy syndrome
(OMIM:253200), is a rare autosomal recessive LSD [19].
MPS VI is caused by homozygous or compound heterozy-
gous mutation in ARSB (OMIM:611542) [20]. The disease
has been estimated to affect 1:200,000–1,500,000 people
worldwide [21]. Pathogenic variants of ARSB result in
reduced or absent activity of the enzyme arylsulfatase
B. The reduced activity leads to high urinary excretion
and intralysosomal accumulation of large amounts of
partially degraded glycosaminoglycans (GAG - previ-
ously also known as a “mucopolysaccharide” dermatan
sulfate) as well as chondroitin sulfate, N-acetyl-
galatosamine and N—acetylgalatosiamine-4,6-disulfate
[22, 23]. GAG accumulation results in cell injury with
a multi-systemic clinical picture of bone abnormal-
ities, collectively referred to as dysostosis multiplex
(disorder of the development of bone, in particular,
the ossification), which affects growth, gait, and
appearance.
Depending on the age of onset and progression of
symptoms, patients with MPS VI have been classified
into severe, intermediate, and “attenuated” forms [24].
The severe form of MPS VI is characterized by very
early onset and severe progression of symptoms with
various skeletal abnormalities (severe dysostosis), includ-
ing dwarfism, facial dysmorphisms, and joint deformities
that affect mobility. Individuals with MPS VI may de-
velop a narrowing of the spinal canal (spinal stenosis) in
the neck, which can compress and damage the spinal
cord. Death generally occurs during childhood or
adolescence.
The attenuated MPS VI form is characterized by very
late onset with affected individuals living nearly normal
life expectancies. Patients have been described with cor-
neal clouding and joint stiffness [25], or mild dysostosis
[26]. The intermediate form shows the middle of the
spectrum of phenotypes, however, no fixed criteria for
separating these descriptive categories are defined.
Since 1991, nearly 100 genetic mutations had been iden-
tified in ARSB in patients with MPS VI [20, 27–30] and
are cataloged in a database (http://mps6-database.org)
[31]. All types of variants can cause all severities of MPS
VI and compound heterozygotes can also affect the sever-
ity of disease [28].
MPS VI in cats
Cowell et al., (1976) [32] reported the first case of an
inherited disorder of mucopolysaccharide metabolism in
the cat. Suzie, a 21-month-old blue point Siamese cat
born of a mother-son mating, presented as “decidedly
small” and “reluctant to walk”. Suzie’s head was “smaller
than normal with an overall shortened and broadened
appearance”. The maxilla was remarkably broadened and
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decreased in length’ (Fig. 1). The cat had bilateral pain at
flection and extension of the joins with radiographic
skeletal striking deformities, multifocal neurologic defi-
cits, corneal clouding, retinal atrophy and significantly
high concentration of mucopolysaccharide in the urine.
A Siamese – Siamese x domestic shorthair cross experi-
mental colony was established and more complete de-
scriptions of pathologic and enzymologic findings were
recorded (Fig. 2) [17, 33]. MPS VI has since been diag-
nosed in Siamese, [34–36] and domestic longhair [37]
cats from different locations and all were reported as
similarly affected (OMIA 000666-9685) [38]. In cats,
autosomal recessive mutation consists of an amino acid
substitution of a wild type leucine to a proline (L476P)
in the arylsulfatase B enzyme, due to a thymine to cyto-
sine transition (c. 1427 T > C) in ARSB [10].
A missense mutation (c.1558G > A), inherited inde-
pendently from L476P and causing an amino acid substi-
tution of the wild type aspartic acid to an asparagine at
codon 520 (D520N) was identified in the same colony
(Fig. 2) [11, 12]. The phenotype of the D520N variant in
combination with the L476P variant was dubbed MPS
VI “mild”. Skin fibroblasts from adult D520N/L476P
compound heterozygous cats expressed approximately
3.1 % of normal levels of ARSB activity and D520N
homozygous cats contained approximately 4.6 %. L476P
homozygous fibroblasts contained very low levels of
ARSB activity at 0.46 %. All 18 colony cats that were
D520N homozygotes were evaluated radiographically up
to 5 years of age. This small increase in residual ARSB
activity is sufficient to prevent the occurrence of degenera-
tive joint disease in D520N homozygous cats. However,
L476P/D520N compound heterozygous cats can develop
severe joint disease as they age [11]. One cat exhibited an
atypical joint disease in the shoulder. Therefore, in the
clinical situation, these animals would most likely be indis-
tinguishable from normal Siamese cats, although more
clinically observable joint lesions could potentially develop
Fig. 1 a Phenotypically normal Siamese dam of the affected cat in b. b Siamese affected cat with ARSB variant causing severe MPS VI disease.
Notice the broad maxillary area, slightly flattened face and half-closed eyes. (Reproduced with permission from Cowell et al., 1976.) [32]
Fig. 2 Alignment of ARSB DNA sequence fragments across mammals. Presented are the wildtype sequences for the domestic cat and other species
and the cat sequences with variants at the nucleotide indicated with a box. The mutation sites are the L476P (CTC to CCC) and the D520N mutation
(GAC to AAC). Note each mutation is on the wildtype sequence background and not compound heterozygotes. Both sites are conserved across
mammals. Alignment produced by ClustalX software. The asterisks indicate conservation of the wildtype nucleotide across all species
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in older animals since the cats were followed only for
5 years [39].
A population screening for both L476P and D520N was
conducted on Siamese cats worldwide [39]. The preva-
lence was investigated in 101 clinically normal cats from
North America, South America, Europe and Australia. In
this general Siamese population, the D520N allelic fre-
quency was 11.4 % (Table 1), but L476P was absent, sug-
gesting either low frequency or higher prevalence within
breeding lines excluded by the sampling. The authors no-
ticed that “the high prevalence in the general population
of the D520N, which might correspond to an expected
D520N/D520N genotype frequency of 1.2 % in the sample,
is “consistent with an extensive presence of carriers, to the
extent two D520N/D520N homozygous were detected”,
suggesting Hardy-Weinberg equilibrium.
Commercial MPS VI screening
Commercial screening has been offered for MPS VI
“mild”, the D520N (c.1558G > A) variant. All data were
generated as fee for service and not based on experimen-
tation. Over 2200 cats have been genotyped and the
variant was identified in 13 different breeds (Table 2), in-
cluding, Abyssinian, Birman, British Shorthair, German
Longhair, Oriental Shorthair, Ragdoll, Russian Blue,
Russian White, Selkirk Rex, Siamese, and Tonkinese.
Most of these breeds have South East Asian origins and
the low occurrence in Western European breeds, such
as British Shorthair, Ragdoll and Selkirk Rex is likely due
to cross breeding. Interestingly, cats with South East
Asian origins, such as Korat and Singapura, and cats
bred from Abyssinians, such as Ocicats, were not found
to have the variant in the populations tested.
Both the ARSB cat variants are variants on the
Illumina 63 K iSelect Infinium DNA array for the cat. In
a survey of approximately 2602 archival cat samples
from various disease and phenotypic projects that were
unrelated to MPS studies, only four domestic cats were
identified as carriers for the severe variant, including a
domestic shorthair, a Siamese, an Ocicat, and a Char-
treux. This low rate could be within the genotyping
error rate of the array. However, 435 were carriers and
103 were homozygous (3.5 %) for the D520N “mild”
variant. A majority of the homozygous and heterozygous
cats were Birmans, as well as many African and Euro-
pean wildcats – suggesting the variant segregates in the
wildcat population and may be a common ancestral
allele.
Conclusion
Genetics is an extremely powerful tool for animal health
care and management because mating of cats can be
controlled. Using genetic testing, cats can be bred in a
manner to prevent illnesses, eliminating problems before
they exist and even eradicating a disease from the popu-
lation. However, genetics must be used wisely, not caus-
ing unwarranted strife and concern or causing
elimination of individuals from a breeding pool that
could make valuable contributions. Thus, researchers
have the responsibility to vigorously define DNA variants
that cause health problems in cats.
In humans, customized newborn screening programs
that are tailored to the ethnicity of the population are
active worldwide, screening for dozens of disease caus-
ing variants [40]. These DNA variants cause health
Table 1 Prevalence of feline ARSB variants in Siamese cats from
the general Siamese population
Origins No. Alleles tested L476P D520N (Percent)
Bristol, England 10 0/10 0/10
Dublin, Ireland 24 0/24 3/24a (12.5 %)
Argentina 4 0/4 2/4b (50 %)
The Netherlands 8 0/8 1/8 (12.5 %)
Melbourne, Australia 132 0/132 14/132c (10.6 %)
Pennsylvania 24 0/24 3/24c (12.5 %)
Total 202 0 23 (11.4)
(reproduced with permission from Crawley et al, 2003) [39]
aTwo animals possibly related
bPossibly littermates
cOne cat was a D520N homozygote
Table 2 Allele frequency of MPS VI variants in cat breeds
Frequency
BREED N L476P D520N
Severe “Mild”
Abyssinian 114 0.00 0.179
Birman 150 0.00 0.313
Birmana 231 0.00 0.359
Birman (Italy)b 51 0.00 0.284
British Shorthair 244 0.00 0.006
Burmese 2 0.00 0.250
German Longhaira 3 0.00 0.333
Oriental Shorthair 5 0.00 0.200
Ragdoll 530 0.00 0.066
Ragdolla 95 0.00 0.131
Russian Blue 44 0.00 0.239
Russian White 4 0.00 0.125
Selkirk Rex 16 0.00 0.063
Siamese 24 0.00 0.104
Somali 65 0.00 0.146
Tonkinese 1 0.00 0.500
39 additional breeds 678 0.00 0.000
aIndicates requested test
bCats tested at Vetogene in Milan, Italy. All other cats were tested at the
Veterinary Genetics Laboratory in Davis, California, USA
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problems where the negative health outcomes can be
thwarted if early intervention can be applied. Concurrent
with the screening programs, the fields of medical genet-
ics and genetic counselling developed. Over 70 different
genetic variants have been identified in cats that confer
coat colors, fur types, morphological attributes, blood
type and diseases [2]. However, formal medical genetic
counselling programs do not exist for companion ani-
mals, thus the researchers and DNA testing laboratories
must fulfill this role for the owners of cats with genetic
diseases.
An uncontrolled selection against D520N is an ex-
ample of how genetic testing can be used unwisely. The
reduction of the already quite low genetic variability in
some pedigreed breeds, such as Birmans, [41–43] which
also have a high frequency of the D520N variant, can re-
duce genetic diversity and perhaps facilitate the prolifer-
ation of more detrimental mutations. Thinking this
mutation must do “something”, breeders tend to find
any health condition, especially common problems due
to overcrowding and stress, and make an unscientific
and highly biased association with disease, including
concerns that are not associated with ARSB variants.
Summary
The relevance of a genetic trait in terms of pain and im-
pediment to function should be considered when pub-
lishing a DNA variant that may ultimately be requested
as a genetic test both by veterinary practitioners and
breeders. Severe genetic dysfunctions need to be tested,
monitored and eventually eradicated. Conversely, elimin-
ation of genetic polymorphisms weakly or not associated
to undefined or mild phenotypic forms endanger the
genetic pool of at risk breeds.
Only the MPS VI L476P (c.1427 T > C) variant in
ARSB causes severe disease in cats. Because the variant
was found in the DNA array survey of unbiased cat
breed sampling, perhaps this disease-associated variant
should be monitored in the cat breed populations, par-
ticularly breeds with Siamese derivations and outcrosses.
However, the ARSB D520N (c.1558G > A) has no evi-
dence of association with disease and the authors rec-
ommend breeders discontinue testing for this variant,
unless in combination with the L476 variant. Testing for
D520N should be considered in heterozygous L476P
cats, however, the L476P variant itself is extremely rare
in the general cat population and should not be tested
unless a MPS disease is suspected. Selection against the
D520N variant is not warranted in cat populations. Re-
searchers and commercial genetic testing laboratories
need to carefully examine the published literature and
perhaps openly discuss issues with genetic testing at for-
ums such as the International Society of Animal Genet-
ics (ISAG; http://www.isag.us/) and with the appropriate
researchers with vested interests in the given disease or
trait. Veterinarians and breeders are encouraged to be
proactive and support research with samples, clinical re-
cords and funds to decipher the causes of health con-
cerns in their cats.
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